Skip to contentC
Castle Biosciences Inc
C
CSTLCastle Biosciences Inc Q2 2022 · 10-Q
Revenue$34.84M$34.84M+53.1% vs Q2 2021 Net Income-$1.65M-$1.65MN/M vs Q2 2021 EPS Diluted-$0.06-$0.06N/M vs Q2 2021 Operating Income-$3,971,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Castle Biosciences Inc · CIK 1447362 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$10,406,000N/M Margins · derivedOperating margin-11.4%+27.3 pt vs Q2 2021
Net margin-4.7%+33.9 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 8, 2022 · 39 d after period end